Status:
COMPLETED
Hemangiol, Post Marketing Surveillance Study
Lead Sponsor:
University Hospital, Montpellier
Conditions:
Infantile Hemangioma
Eligibility:
All Genders
Up to 18 years
Brief Summary
Infantile hemangioma is a benign tumor belonging to the group of vascular tumors in the ISSVA classification (International Society for the Study of Vascular Anomalies). The diagnosis is clinical and ...
Detailed Description
This study is retrospective, longitudinal, descriptive and observational. Children aged 0 to 1 years hospitalized for introduction of Hemangiol between January 2014 and November 2018 will be included....
Eligibility Criteria
Inclusion
- Inclusion criteria:
- \- Child from 0 to 18 years old hospitalized for introduction of Hemangiol between January 2014 and November 2018
- Exclusion criteria:
- \- Patients refuse the use of medical data will be excluded.
Exclusion
Key Trial Info
Start Date :
July 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 30 2019
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT04105517
Start Date
July 1 2019
End Date
October 30 2019
Last Update
December 2 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Uh Montpellier
Montpellier, France, 34295